slide5.jpg slide4.jpg slide3.jpg slide2.jpg slide1.jpg

MIMETAS raises 5.2 million dollar for organ-on-a-chip

MIMETAS B.V. has raised 5.2 million dollar to fund its expansion as a global leader in organ-on-a-chip technology. Venture capital investors Zeeuws Investerings Fonds (ZIF) and the Participatiemaatschappij Oost Nederland (PPM) have joined forces with national and regional partners to fund development and sales of MIMETAS’ unique 3D disease- and tissue modelling technologies.

Jos Joore, co-founder and Chief Business Officer at MIMETAS, acknowledges that these resources arrive at a strategically important moment: “Collaborations with top-tier pharmaceutical companies are expanding rapidly, an example of this is the recently announced 1.6 million dollar kidney-on-a-chip project with Roche, Pfizer and GlaxoSmithKline. The funds will be used to scale up the production of OrganoPlates and strengthen our activities in predictive preclinical model development, thus consolidating our leadership in this highly competitive field.” Currently, MIMETAS has a range of disease-, toxicology- and ADME models planned, in various stages of development and validation.

Read the whole press release here.

Johan Sebregts (ZIF), Jan-Frens van Giessel (PPM Oost) and Jos Joore, Bas Trietsch and Paul Vulto (MIMETAS) toast to signing the investment agreement

 
More information:
MIMETAS, Jos Joore – pr@mimetas.com – +31.85.888.3161